Retention of triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine compared to combination methotrexate and leflunomide in rheumatoid arthritis
Authors' conclusion
Patients on triple therapy remained on treatment longer than patients on double therapy. However, this difference was not statistically significant.
Study context
- Population
- Patients with rheumatoid arthritis (RA) from the Ontario Best Practices Research Initiative (OBRI) who received triple or double therapy on or after OBRI enrolment
- Participants
- 692 patients
- Exposure
- Triple therapy vs double therapy
- Triple therapyn = 258
- Double therapyn = 434reference
- Outcome
- Treatment retention
Methodological detailsreal-world, registry-based (OBRI)
- Real-world
- Registry-based (OBRI)
Main finding
As reported in the abstract
Treatment retention (median survival on treatment)
| Group | Value | Discontinuations |
|---|---|---|
| Triple therapy | median 15.1 (95% CI 11.2–21.2) months | 175 (67.8%) |
| Double therapy | median 9.6 (95% CI 7.03–12.2) months | 287 (66.1%) |
Value
Triple therapymedian 15.1 (95% CI 11.2–21.2) months
Double therapymedian 9.6 (95% CI 7.03–12.2) months
Discontinuations
Triple therapy175 (67.8%)
Double therapy287 (66.1%)
Observational data: associations, not effects.
Further findings
Mean
| Outcome | Triple therapy | Double therapy | P value |
|---|---|---|---|
| Mean DAS28-ESR · 6 months | 3.4 | 3.9 | P < 0.0001 |
| Mean DAS28-ESR · 12 months | 3.2 | 3.5 | P = 0.0005 |
Original publication
Retention of triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine compared to combination methotrexate and leflunomide in rheumatoid arthritis. Joint Bone Spine. Published 5 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →